They've still got a way to go tonymcm.
My best guess would be first dose in Q1, 2025 and data in Q2,2025. Seems to me the positive feedback from FDA on trial design and manufacturing is a step closer to getting IND status, but they still need to run IND enabling studies, site selection and the like.
Value inflection in the short term is more likely from ALA-5 pre-clinical, then in vivo, studies.
Ann: Positive pre-IND feedback from FDA for ALA-101, page-12
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.005(2.56%) |
Mkt cap ! $199.8M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.5¢ | 19.0¢ | $570.4K | 2.873M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 389017 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 70000 | 2 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| ALA (ASX) Chart |